Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 337 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: The Methodist Hospital Research Institute Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Transform Kidney Care and Improve Pursuit of Transplant

NCT07794631
View directory record Official record
Conditions
Kidney Disease, Kidney Transplant, Deceased Donor Kidney Transplant, Living Donor Kidney Transplantation, Chronic Kidney Disease (Stages 3b-5)
Interventions
Digital Health Integration, Training for Early Transplant Access and Support, Kidney Health Mobile Health (mHealth) Application
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Active, not recruiting Phase 1 Interventional

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

NCT00902044
View directory record Official record
Conditions
Sarcoma
Interventions
Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide, Autologous CAR Positive T cells
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2032
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Study in ALS With Abatacept & IL-2

NCT06307301
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

NCT00711035
View directory record Official record
Conditions
Adenovirus Infection, EBV Infection
Interventions
Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 11, 2026, 7:20 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 1 Interventional Results available

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions
L-NMMA, Pembrolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dexamethasone for Ureteral STent Symptoms (DUSTS)

NCT06930690
View directory record Official record
Conditions
Ureteral Stent-Related Symptom
Interventions
Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

NCT01097642
View directory record Official record
Conditions
Breast Cancer
Interventions
Cetuximab, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 11, 2026, 7:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

NCT03596086
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade III
Interventions
ADV/HSV-tk (gene therapy)
Drug
Lead sponsor
David Baskin MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Not listed Not applicable Interventional

Intraperitoneal and Extraperitoneal Uterosacral Ligament Suspensions for Post-Hysterectomy Vaginal Vault Prolapse

NCT04172896
View directory record Official record
Conditions
Vaginal Vault Prolapse, Post-Hysterectomy Vaginal Vault Prolapse, Prolapse, Vaginal
Interventions
Intraperitoneal Uterosacral Ligament Suspension, Extraperitoneal Uterosacral Ligament Suspension
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 11, 2026, 7:20 AM EDT
Active, not recruiting Phase 1 Interventional

Administration of Donor T Cells With the Caspase-9 Suicide Gene

NCT01494103
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Non Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytosis, Familial Hemophagocytic Lymphohistiocytosis, Hemophagocytic Syndrome, Epstein Barr Virus Infection, X-linked Lymphoproliferative Disease
Interventions
iCaspase9-transduced T cells, AP1903
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

NCT03724331
View directory record Official record
Conditions
Fatigue, Self Efficacy, Quality of Life, Physical Activity, Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Light Physical Activity 1, Light Physical Activity 2, Support Education Activity
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Not listed Phase 4 Interventional

Single Dose rATG for Renal Allograft Rejection

NCT02102854
View directory record Official record
Conditions
Acute (Cellular) Renal Allograft Rejection
Interventions
rATG
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 11, 2026, 7:20 AM EDT
Not listed Phase 2 Interventional

Phase II Clinical Trial of Interleukin-2 in AD

NCT06096090
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interleukin-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 11, 2026, 7:20 AM EDT
Recruiting Phase 4 Interventional

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

NCT06511232
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Interventions
Intraosseous Morphine
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

NCT00447473
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, Ketoconazole, Mitoxantrone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 11, 2026, 7:20 AM EDT
Recruiting Phase 1 Interventional

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

NCT06345027
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T-Cell
Interventions
Treatment Arm A
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

68 Ga-PSMA for High Risk Prostate Cancer

NCT04614363
View directory record Official record
Conditions
Prostate Cancer, High Risk
Interventions
68Ga-PSMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 11, 2026, 7:20 AM EDT
Enrolling by invitation No phase listed Observational

Surgical Site Infection Outcomes in Natural Orifice Intracorporeal Anastomosis and Extraction (NICE) Procedure - The NICE Trial

NCT06957236
View directory record Official record
Conditions
Diverticulitis, Surgical Site Infection, Surgical Site Infections, Colorectal Surgery, Robotic Surgical Procedures, Clinical Trials, Diverticulitis, Colonic, Diverticulitis Colon, Diverticulitis; Perforation, Bowel
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 11, 2026, 7:20 AM EDT
Active, not recruiting Phase 1 Interventional

Neoadjuvant Atezolizumab in Cutaneous Melanoma

NCT04020809
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Atezolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

NCT01446016
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Paclitaxel, Docetaxel, Abraxane, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant

NCT02181114
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expert System Coaching
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 11, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Feasibility and Acceptability of ReCognitionVR-based Cognitive Stimulation in Surgical Patients

NCT06232317
View directory record Official record
Conditions
Surgery, Delirium, Delirium, Post-Operative
Interventions
Virtual Reality Software, Traditional Orientation Methods
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 11, 2026, 7:20 AM EDT